Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

El ensayo es el primero en humanos, de fase I, abierto y de aumento de dosis para evaluar la seguridad y tolerabilidad de ES2B-C001 combinado con montanida o sin montanida, en pacientes con receptor 2 del factor de crecimiento epidérmico humano (HER2) Expresando cáncer de mama metastásico

15 de septiembre de 2026 actualizado por: ExpreS2ion Biotechnologies

Un primer ensayo de fase I, abierto y de aumento de dosis en humanos para evaluar la seguridad, tolerabilidad e inmunogenicidad/actividad antitumoral preliminar de ES2B-C001 con o sin montanida en cáncer de mama metastásico que expresa HER2

The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without [adjuvant], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.

Descripción general del estudio

Estado

Activo, no reclutando

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Graz, Austria
        • Medical University of Graz
      • Linz, Austria, 4010
        • Ordensklinikum Linz GmbH Barmherzige Schwestern
      • Vienna, Austria, 1090
        • Medical University Of Vienna

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients aged ≥18 years at screening visit.
  • Diagnosis of HER2-expressing locally advanced, unresectable, or metastatic BC, with HER2 IHC level 1+, 2+ (either FISH negative or positive), or IHC level 3+, after undergoing 2-3 lines of anticancer therapy.
  • Life expectancy of at least 3 months.
  • ECOG performance status 0-2.
  • Patients have adequate bone marrow, kidney, liver, heart, and lung function without clinically significant laboratory parameters as judged by the investigator.
  • 12-lead ECG without clinically significant abnormalities and no LBBB, QRS duration >140 ms, or evidence of prior infarction.
  • Recovered from side effects, adverse reactions, or adverse events due to prior therapy and/or surgery; any residual toxicities and toxicities related to current anticancer treatment must be ≤ Grade 2, except for alopecia, neuropathy or lymphoedema.
  • If female, non-pregnant, postmenopausal, or practicing reliable contraception.
  • If male, sterilized or using reliable contraception.

Exclusion Criteria:

  • Any planned intravenous chemotherapy regimens or check point inhibitors, or previous therapy with those agents during the past 1 month and the patients are neutropenic. Maintenance therapy with a stable dose of HER2-directed mAbs or treatment with antibody drug conjugates (ADCs) for metastatic BC is allowed at the discretion of the treating physician.
  • Symptomatic CNS metastatic disease requiring treatment with high dose steroids (i.e., above 10 mg of prednisone or equivalent) within 14 days prior to first administration of ES2B-C001 (with or without adjuvant).
  • Concurrent or recent (within 21 days or 5 half-lives) involvement in any other clinical trial with an investigational drug, device, or other experimental intervention.
  • Concomitant severe or uncontrolled underlying medical and/or mental disease unrelated to the tumor, which in the opinion of the investigator is likely to compromise patient safety and affect the trial's outcome.
  • Previous documented coronary artery disease or congestive heart failure (>NYHA II).
  • Echocardiography with LVEF <50%.
  • Uncontrolled hypertension.
  • Active, known, or suspected autoimmune disease, except thyroid conditions sufficiently controlled on thyroid hormone therapy, and controlled insulin dependent diabetes.
  • Necessity for long-term immunosuppression (≤ 4 mg dexamethasone may be used transiently).
  • Systemic infection requiring intravenous antibiotics within 14 days before dosing.
  • Chronic use of anti-viral agents, except for human immunodeficiency virus (HIV) or hepatitis B or C virus (HBV, HCV) treatments.
  • History of severe hypersensitivity reactions to any of the trial drug components.
  • Has received a live or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Note: Administration of inactivated or recombinant vaccines/killed vaccines are allowed.
  • Birthmarks, tattoos, wounds, or skin conditions on deltoid region/buttocks that may obscure the assessment of injection site reactions.
  • Female patients who are pregnant, or lactating.
  • Any infection (including SARS-CoV-2), that in the opinion of the investigator would, upon inclusion in the trial, lead to potentially harming patients' safety or integrity.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cohorte C1: 50 µg ES2B-C001 con [adyuvante]

Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations.

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Experimental: Cohorte C2: 150 µg ES2B-C001 con [adyuvante]

Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations.

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Experimental: Cohorte C3: 450µg ES2B-C001 con o sin [adyuvante]

Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations.

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To determine the safety, tolerability, maximum tolerated dose (MTD) for ES2B-C001 alone or in combination with [adjuvant].
Periodo de tiempo: From enrolment to the end of study at week 18
  • Nature and frequency of dose-limiting toxicities (DLTs).
  • Incidence, nature and severity of AEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
  • Incidence, nature and severity of injection site reactions according to FDA Guidance on Toxicity Grading Scales in Vaccine Trials (FDA, 2007).
From enrolment to the end of study at week 18

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Periodo de tiempo: From enrolment to the end of study at week 18

Immunogenicity as humoral immune response: Total anti-HER2 Immunoglobulin G (IgG) and IgG lambda titers in sera by enzyme-linked immunosorbent assay (ELISA).

From enrolment to the end of study at week 18

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Periodo de tiempo: From enrolment to the end of study at week 18

Percentage of patients with measurable disease at baseline achieving Complete Remission (CR) or Partial Response (PR) according to RECIST 1.1 as assessed by the investigator during routine follow up.

From enrolment to the end of study at week 18
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Periodo de tiempo: From enrolment to the end of study at week 18

Percentage of patients with Disease Control Rate (DCR) according to RECIST 1.1 as assessed by the investigator during routine follow up.

From enrolment to the end of study at week 18
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Periodo de tiempo: From enrolment to the end of study at week 18

Progression free survival (PFS) in patients with Stable Disease (SD), or PR, at the time of first dosing of ES2B-C001 alone or in combination with [adjuvant] according to RECIST 1.1.

From enrolment to the end of study at week 18
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Periodo de tiempo: From enrolment to the end of study at week 18

Overall survival (OS)

From enrolment to the end of study at week 18
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Periodo de tiempo: From enrolment to the end of study at week 18

Optionally, other immunogenicity and biomarker readouts: characterization of anti-HER2 immunoglobulins in selected sera, including isotyping (e.g. IgM, IgG and IgG subclasses IgG1-4, IgD, IgE, IgA); analysis of HER2 epitope recognition profiles; cellular immune responses; in vitro cell stimulation assays; and measuring circulating tumor DNA.

From enrolment to the end of study at week 18

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Thomas K. Jorgensen, ExpreS2ion Biotechnologies

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de junio de 2025

Finalización primaria (Estimado)

1 de diciembre de 2026

Finalización del estudio (Estimado)

1 de septiembre de 2028

Fechas de registro del estudio

Enviado por primera vez

12 de diciembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

17 de diciembre de 2024

Publicado por primera vez (Actual)

24 de diciembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ES2B-C001-S01
  • 2024-516333-12-00 (Ctis)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Within the study de-identified patient data will be shared with

  • the operational study team, sponsor, auditor and for reporting of safety events to the regulatory agencies and EC
  • Data Monitoring Committees/ or other independent committees during the study
  • At the end - data listings are part of the Appendices of the CSR which will be shared to regulatory agencies and EC

Tipo de información de apoyo para compartir IPD

  • SAVIA
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir